Backgrounds/Aims: Hepatic arterial infusion chemotherapy (HAIC) has been reported as an effective treatment for advanced hepatocellular carcinoma. The aim of this study is to compare the effect and safety between a high-dose regimen (750 mg/m 2 5-fluorouracil [FU] and 25 mg/m 2 cisplatin on day 1-4) and a low-dose regimen (500 mg/m 2 5-FU on day 1-3 with 60 mg/m 2 cisplatin on day 2).
http://www.livercancer.or.kr (HAIC) can be other options. In a study of advanced HCC cases in the Asian-Pacific area, patients treated with sorafenib survived only 2 to 3 months longer than the control group. 3 According to many studies, combined treatments resulted in better outcomes compared to sorafenib alone. 4 In HAIC, chemo-agents are infused directly into the hepatic artery through an implanted catheter, providing higher local concentrations and lower systemic side effects. 5, 6 Although it has clinical efficacy for advanced HCC with portal vein thrombosis including infiltrating types, HAIC has limitations for standardized therapy due to lack of unified protocols, diverse indications, differences in response rate, deterioration of liver and bone marrow function, catheter-related problems, and other issues. 7 In spite of variable response rates from 7 to 81%, some studies have reported a dramatic response to HAIC in some patients with advanced HCC. A multicenter study in South Korea showed that patients treated with HAIC had better outcomes than those treated with sorafenib for advanced HCC with portal vein invasion. [8] [9] [10] There are several kinds of chemo-agents for HAIC, of which a combination of 5-fluorouracil (5-FU) and cisplatin is the most commonly used. 11 The efficacy of this regimen varies from 5.0-19.5 months of median overall survival (OS) and 3.8-38.5% of response rate. These unstable outcomes are due to stage of cancer, existence of portal vein thrombosis, baseline liver function, and dose of chemo-agents etc. 7, [11] [12] [13] High-dose chemotherapy usually has better efficacy than low-dose chemotherapy, but it carries a higher risk of deteriorating liver function or of having side effects. 7 There is a lack of studies on the optimal dose of chemo-agents in HAIC. Therefore, we aimed to compare the efficacy and safety of high-dose 5-FU/cisplatin to that of low-dose 5-FU/ cisplatin.
Methods

Patients
This study was conducted as a retrospective cohort study.
We reviewed the medical records of patients who were treated with HAIC between September 2010 to December 2016. 
Treatment protocol
Based on studies previously reported in South Korea, patients were divided into the high-and low-dose groups. 
Statistical analysis
Results were reported as mean (±standard deviation), number (%), or median (95% CI) and comparisons were performed using Student's t-tests, Chi-square tests or Fisher's exact tests. Survival outcomes were estimated using the Kaplan-Meier method and compared by log-rank tests. 
Treatment response
According to mRECIST, CR, PR, SD, and PD were noted in one (3.1%), 15 (46.9%), three (9.4%), and 13 patients (40.6%) in the high-dose group, and 0 (0%), one (6.3%), eight (50.0%), and seven patients (43.8%) in the low-dose group, respectively (P =0.002). The disease control rate (CR, PR, and SD) did not differ between groups (59.4% vs. 56.3%, P =1.000), but the objective response rate (CR and PR) was significantly higher in the high-dose group (50.0% vs. 6.3%, P=0.003), (Table 2) .
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Treatment-related adverse events
The frequency of total adverse events was similar, 90.6%
(29/32) in the high-dose group and 87.5% (14/16) Many studies showed various results on response to HAIC.
The objective response rate of the 5-FU/cisplatin regimen that most widely used in South Korea was reported as 22 to 32%, and CR rate was also reported in 2 to 6%. 8, 11, 14, 15 The high-dose group in this study was infused separated dose daily for a few days rather than infusing at once, in order to increase whole dose of chemo-agents and prolong duration of exposure to chemo-agents. In the high-dose group had a better objective response rate (high-dose group, 50.0% vs.
low-dose group, 6.3%), and a higher incidence of severe adverse events over grade 2 (high-dose group, 43.8% vs. lowdose group, 12.5%). But there were no clinically uncontrolled adverse events in both two groups. Compared to another study using high-dose of cisplatin and 5-FU, this study showed a better objective response rate and a similar incidence of hematologic adverse events. 14 These results may be attributed to baseline characteristics of the patients, exclusion of large HCC covering over 50% of the liver surface and inclusion of patients with TACE refractoriness in BCLC stage B.
The duration of HAIC treatment is not established. HAIC does not always guarantee good response and further study should be done to establish how many cycles are adequate.
Repeated and long-term exposure to the same chemo-agents may make intolerance of HCC, and cause liver function deterioration, bone marrow suppression, and malnutrition due to toxicities. 16 So we thought that more than six cycles of HAIC should be avoided. In this study, one patient who underwent 18 cycles of HAIC became weak and cachexic, and finally died of pneumonia. And early prediction of tumor response is possible because significant decrease in tumor markers and tumor sizes after 1-2 cycles is observed in most of patients with good response to HAIC. 17, 18 So we finished HAIC early in patients who showed PD after 2 cycles, and continued HAIC up to 6 cycles for those who showed SD and PR after 2 cycles. And sequential treatments such as resection, TACE, target therapy, and radiotherapy were carried out according to the status of tumor and patients. Therefore, it is necessary to evaluate the role of HAIC as a bridging therapy to decrease size of tumor and to improve efficacy of sequential rescue therapy such as targeted agents rather than maintenance therapy. 19, 20 This study has some limitations. First, this study is a single center, retrospective study with many biases. Second, there were heterogenous stages in the two groups with more intermediate stage patients in the high-dose group, and this factor affected treatment response and survival.
In conclusion, HAIC with high-dose 5-FU/Cisplatin may achieve better tumor response and may improve survival compared to a low-dose regimen for advanced HCC with preserved liver and bone marrow function. However, highdose regimens should be administered cautiously because of higher incidence of adverse events. More studies are needed to determine the adequate cycles of HAIC, and this should establish a role HAIC as a bridging therapy combined with other options such as target therapy.
